Redwire plans to expand pharmaceutical manufacturing research in orbit through an agreement between its SpaceMD subsidiary and SpaceX to fly up to 32 drug-crystallization laboratories on a 2028 Starfall mission.<\/p>\n
The contract, announced during Redwire\u2019s second-quarter earnings call, represents the first dedicated commercial mission for SpaceX\u2019s Starfall reentry capsule. The spacecraft made its debut in June with a ride-along experiment rather than a dedicated customer mission.<\/p>\n
The planned flight would also represent the largest dedicated commercial microgravity research mission announced to date, according to the company.<\/p>\n
SpaceMD\u2019s PIL-BOX technology is designed to crystallize pharmaceutical compounds in microgravity, allowing researchers to investigate improved drug formulations and potential new medicines.<\/p>\n
The system has already been used extensively in orbit. Since 2023, 54 PIL-BOX laboratories have flown to the International Space Station, conducting crystallization experiments involving 45 different compounds. Another 12 units are scheduled to fly this year.<\/p>\n
For the Starfall mission, SpaceMD is developing a new PIL-BOX configuration specifically designed to optimize research operations aboard the reentry vehicle.<\/p>\n
\n\u201cSpaceMD\u2019s Starfall mission provides a major leap forward in scaling our microgravity capabilities,\u201d Redwire Chairman and CEO Peter Cannito said during the call.<\/p>\n<\/blockquote>\n
Cannito said the partnership with SpaceX would provide a new route for commercial microgravity manufacturing at greater scale.<\/p>\n
SpaceMD CEO John Vellinger said the company expects the combination of its flight-tested payload technology and SpaceX\u2019s transportation platform to increase research opportunities and accelerate pharmaceutical development.<\/p>\n
\n\u201cWe\u2019re dramatically expanding our ability to serve customers, increase research cadence, and accelerate the creation of life-changing therapies,\u201d Vellinger said.<\/p>\n<\/blockquote>\n
Reentry Capsules Target Pharmaceutical Research<\/h2>\n
Pharmaceutical development has become an important application for commercial reentry vehicles because they can provide controlled microgravity environments while allowing research materials to return to Earth relatively quickly for analysis.<\/p>\n
Starfall also offers a potential alternative for commercial researchers as the International Space Station moves toward retirement. Dedicated free-flying missions could allow companies to schedule microgravity experiments without relying on ISS crew availability or station manifesting constraints.<\/p>\n
For SpaceMD, the Starfall agreement provides an opportunity to move beyond individual experiments and increase the frequency and scale of pharmaceutical research conducted in space.<\/p>\n
The companies did not disclose whether the contract covers additional Starfall missions or identify specific drug candidates that will be studied during the 2028 flight.<\/p>\n","protected":false},"excerpt":{"rendered":"
Redwire plans to expand pharmaceutical manufacturing research in orbit through an agreement between its SpaceMD subsidiary and SpaceX to fly up to 32 drug-crystallization laboratories on a 2028 Starfall mission. The contract, announced during Redwire\u2019s second-quarter earnings call, represents the first dedicated commercial mission for SpaceX\u2019s Starfall reentry capsule. The spacecraft made its debut in […]<\/p>\n","protected":false},"author":1,"featured_media":80884,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[10071,5786,10072,10073,717,10074,10075,6210,5812,10076,10077,10078,10079,4697,6416,5783,393,10080,316,677,5841],"class_list":["post-80883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-2028-mission","tag-commercial-spaceflight","tag-drug-crystallization","tag-in-space-pharmaceuticals","tag-international-space-station","tag-john-vellinger","tag-microgravity-manufacturing","tag-microgravity-research","tag-north-america","tag-peter-cannito","tag-pharmaceutical-manufacturing","tag-pharmaceutical-research","tag-pil-box","tag-redwire","tag-reentry-capsule","tag-space-industry","tag-space-manufacturing","tag-spacemd","tag-spacex","tag-starfall","tag-united-states"],"acf":[],"_links":{"self":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/80883"}],"collection":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/comments?post=80883"}],"version-history":[{"count":0,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/80883\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/media\/80884"}],"wp:attachment":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/media?parent=80883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/categories?post=80883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/tags?post=80883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}